1. In Vivo
  2. >>Archive

Start-Up Previews (10/2011)

This Month's Profile Group: The New Ophthalmic Drug Players, features profiles of Imagen Biotech, KalVista Pharmaceuticals, ONL Therapeutics and Xcovery Vision. Plus these Start-Ups Across Health Care: Acetylon Pharmaceuticals, Aleva Neurotherapeutics, cermaVEIN and Flex Biomedical.

With time to exit an increasingly important metric for VCs, jump-starting new companies via in-licensing remains an important and oft-used strategy. Such derisking is one of the defining principles behind ophthalmology focused start-ups like Lux Biosciences, Ophthotech and PanOptica. Imagen Biotech Inc., a new ophthalmic play still operating in stealth mode, is no different. It plans to pursue new leads for sight-threatening diseases, including dry age-related macular degeneration.

Also see "Imagen Biotech Inc." - Scrip, 1 October, 2011.

More from Archive

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.